Skip to main content
. Author manuscript; available in PMC: 2018 Aug 10.
Published in final edited form as: Oncogene. 2016 Apr 4;35(40):5295–5303. doi: 10.1038/onc.2016.70

Figure 4. Autophagy inhibition sensitizes BRAF-mutant melanoma cells to vemurafenib in vitro.

Figure 4.

(a) Western blots showing LC3B-II and p62 accumulation in YUKSI melanoma cells treated with autophagy blockers (CQ or Baf) for 72 h. (b) YUKSI melanoma cells were treated with DMSO or 1 μM vemurafenib, alone or in combination with autophagy blockers (CQ or Baf) for 72 h; Left—Cells remaining attached to the plate were fixed and DAPI stained to visualize the surviving population. Right—Data represent mean±s.e.m. across four different fields of view. (c) Western blots showing LC3B and p62 levels in YUKSI melanoma cells expressing a control (shCntrl) or two different shATG5 hairpins (shATG5–1 and shATG5–2). (d) shCntrl or shATG5 YUKSI melanoma cells were treated with DMSO or 1 μM vemurafenib, alone or in combination for 72 h; Left—Cells remaining attached to the plate were fixed and DAPI stained to visualize the surviving population. Right—Data represent mean±s.e.m. across eight different fields of view. ***P<0.001; ****P<0.0001.